ArticleAdvances in therapy2025

First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.

Jianming Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.